On October 2, 2019 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, reported acceptance of a presentation at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) being held November 6–10, 2019 in National Harbor, Maryland (Press release, Unum Therapeutics, OCT 2, 2019, View Source [SID1234540015]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our BOXR platform aims to discover novel transgenes co-expressed with chimeric-targeting receptors to improve T cell functionality in the solid tumor microenvironment," said Seth Ettenberg, Ph.D., Chief Scientific Officer of Unum. "At this year’s SITC (Free SITC Whitepaper) meeting, we are pleased to present preclinical data from BOXR1030, our first product candidate from this platform, and the role of the addition of the GOT2 transgene to the BOXR1030 construct that was discovered as part of this effort."

Unum’s poster presentation at SITC (Free SITC Whitepaper):

Title: Co-expression of the Metabolic Enzyme GOT2 with a GPC3-Targeted CAR-T Overcomes Challenges of the Solid Tumor Microenvironment, Substantially Improving Therapeutic Efficacy in Solid Tumor Xenografts (Abstract #P227)
Date: Friday November 8, 2019